Known targets — ChEMBL curated mechanism
BTKCACNA1CCACNA1DCACNA1FCACNA1SCACNA2D1CACNA2D2DRD2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQHRH1HTR2AP2RY12
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.80 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HTR6 | P50406 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | NT5E | P21589 | 1/20 | 0.46 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | MMP1 | P03956 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL27820715 | 0.98 | TSHR (0.76) | TSHRSMN1; SMN2POLBCYP2D6BCAT1 | |
| Acetic Acid SCHEMBL6005462 | 0.95 | SMN1; SMN2 (0.73) | TSHRSMN1; SMN2POLBCYP2D6BCAT1 | |
| Acetone SCHEMBL27970561 | 0.95 | TSHR (0.80) | TSHRSMN1; SMN2POLBCYP2D6BCAT1 | |
| SCHEMBL27485433 | 0.93 | TSHR (0.76) | TSHRSMN1; SMN2POLBCYP2D6BCAT1 | |
| Acetamide SCHEMBL7845790 | 0.91 | TSHR (0.73) | TSHRSMN1; SMN2POLBCYP2D6BCAT1 | |
| Ethane SCHEMBL4196548 | 0.90 | TSHR (0.89) | TSHRSMN1; SMN2POLBCYP2D6BCAT1 | |
| Bicarbonate SCHEMBL15282245 | 0.90 | TSHR (0.89) | TSHRSMN1; SMN2POLBCYP2D6BCAT1 | |
| Methyl Alcohol SCHEMBL2996522 | 0.90 | TSHR (0.89) | TSHRSMN1; SMN2POLBCYP2D6BCAT1 | |
| Bicarbonate SCHEMBL28272077 | 0.90 | TSHR (0.89) | TSHRSMN1; SMN2POLBCYP2D6BCAT1 | |
| Benzene SCHEMBL9751882 | 0.89 | TSHR (1.00) | TSHRSMN1; SMN2POLBCYP2D6LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119235806-A | Meloxbaline besylate tablet containing excellent stabilizer and preparation method thereof | 江苏艾立康医药科技有限公司 | 2025-01-03 | — | — | CN | claimed |
| CN-118286172-A | Solid pharmaceutical preparation containing a stabilizer | 第一三共株式会社 | 2024-07-05 | — | — | CN | claimed |
| CN-117623957-A | Synthesis method of milbelin benzenesulfonate diastereoisomer [ (1R, 5S, 6R) -6- (aminomethyl) -3-ethylbicyclo [3.2.0] hept-3-en-6-yl ] acetic acid benzenesulfonate | 中国药科大学 | 2024-03-01 | — | — | CN | claimed |
| CN-114402198-A | Impurity detection method for 2- ((1S,2S,3R,6S,8S) -2- (aminomethyl) tricyclo [4.2.1.03,8] nonane-2-yl) acetic acid benzene sulfonate or composition thereof | 四川海思科制药有限公司 | 2022-04-26 | — | — | CN | claimed |
| WO-2021043117-A1 | IMPURITY DETECTION METHOD FOR 2-((1S,2S,3R,6S,8S)-2-(AMINOMETHYL)TRICYCLO[4.2.1.0 3,8]NONANE-2-YL)ACETATE BENZENESULFONATE OR COMPOSITION THEREOF | 四川海思科制药有限公司 | 2021-03-11 | — | — | WO | claimed |
| CN-103610674-B | Solid preparation containing micronized prasugrel | HAINAN LINGKANG PHARMACEUTICAL | 2015-01-07 | — | — | CN | claimed |
| CN-103610674-A | Solid preparation containing micronized prasugrel | HAINAN LINGKANG PHARMACEUTICAL | 2014-03-05 | — | — | CN | claimed |
| US-20120295930-A1 | NOVEL PROCESS FOR THE PREPARATION OF CIS-NUCLEOSIDE DERIVATIVE | MYLAN LABORATORIES LIMITED (IN) | 2012-11-22 | — | — | US | claimed |
| WO-2011095987-A1 | NOVEL PROCESS FOR THE PREPARATION OF CIS-NUCLEOSIDE DERIVATIVE | MATRIX LABORATORIES LTD. (IN) | 2011-08-11 | — | — | WO | claimed |
| WO-2011021214-A2 | IMPROVED PROCESS FOR THE PREPARATION OF (S)-2-AMINO-4,5,6,7-TETRAHYDRO-6 - (PROPYLAMINO) BENZOTHIAZOLE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | MSN LABORATORIES LIMITED (IN) | 2011-02-24 | — | — | WO | claimed |
| CN-101878193-A | Bicyclic gamma-amino acid derivatives | DAIICHI SANKYO CO LTD | 2010-11-03 | — | — | CN | claimed |
| CN-122075463-A | Pharmaceutical composition containing melagatran besylate and preparation method thereof | — | 2026-05-26 | — | — | CN | disclosed |
| CN-122005480-A | Meloxepin besylate tablet and preparation method thereof | 山东鲁抗医药股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| CN-119970683-A | Milobulin besylate double-release preparation and preparation method thereof | 中国海洋大学 | 2025-05-13 | — | — | CN | disclosed |
| CN-119818470-A | Pharmaceutical composition containing melagatran besylate and preparation method thereof | 齐鲁制药(海南)有限公司 | 2025-04-15 | — | — | CN | disclosed |
| WO-2010042392-A2 | HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2010-04-15 | — | — | WO | disclosed |
| US-20100087419-A1 | HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME LLC | 2010-04-08 | — | — | US | disclosed |
| US-20040048906-A1 | Synergistic combinations of amlodipine and atorvastatin used to treat angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and to treat subjects with symptoms of cardiac risk | BUCH JAN (US) | 2004-03-11 | — | — | US | disclosed |
| CN-1135521-A | Granular detergent composition | KAO CORP (JP) | 1996-11-13 | — | — | CN | disclosed |
| EP-0079447-A1 | Deazapurine derivatives | Takeda Chemical Industries, Ltd. (JP) | 1983-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087419-A1 | HIV INTEGRASE INHIBITORS | POLB, CCNB1, POLR2A | TSHR 4224/4885SMN1; SMN2 3483/4885POLB 1/4885 |
| US-20120295930-A1 | NOVEL PROCESS FOR THE PREPARATION OF CIS-NUCLEOSIDE DERIVATIVE | DDX1, NSUN2, SLC29A1 | TSHR 3024/4885SMN1; SMN2 3193/4885POLB 200/4885 |
| US-20040048906-A1 | Synergistic combinations of amlodipine and atorvastatin used to treat angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and to treat subjects with symptoms of cardiac risk | HMGCR, PCSK9, LDLR | TSHR 4048/4885SMN1; SMN2 4649/4885POLB 4643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.